Usefulness of dermoscopy to improve the clinical and histopathologic diagnosis of skin cancers - 14/01/19
Abstract |
Multiple studies have shown that dermoscopy increases the sensitivity and specificity for the detection of skin cancers compared with examination by the naked eye. Dermoscopy can also lead to the detection of thinner and smaller cancers. In addition, dermoscopy leads to the more precise selection of lesions requiring excision. In essence, dermoscopy helps clinicians differentiate benign from malignant lesions through the presence or absence of specific dermoscopic structures. Therefore, because most dermoscopic structures have direct histopathologic correlates, dermoscopy can allow the prediction of certain histologic findings present in skin cancers, thus helping select management and treatment options for select types of skin cancers. Visualizing dermoscopic structures in the ex vivo specimens can also be beneficial. It can improve the histologic diagnostic accuracy by targeted step-sectioning in areas of concern, which can be marked by the clinician before sending the specimen to the pathologist, or by the pathologist on the excised specimen in the laboratory. In addition, ex vivo dermoscopy can also be used to select tumor areas with genetic importance because some dermoscopic structures have been related to mutations with theragnostic relevance. In the second article in this continuing medical education series, we review the impact of dermoscopy on the diagnostic accuracy of skin cancer, how dermoscopy can affect the histopathologic examination, and which dermoscopic features may be more relevant in terms of histologic and genetic prediction.
Le texte complet de cet article est disponible en PDF.Key words : dermoscopy, histology, histopathology
Abbreviations used : AK, BCC, BMR, EVD, NEE, SCC
Plan
Supported by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748 and the Beca Excelencia Fundación Piel Sana (Dr Yélamos). |
|
Dr Gerami has served as a consultant to and has received honoraria from Myriad Genomics, DermTech, and Castle Biosciences. Dr Marghoob has served as a consultant to and received honoraria from 3Gen. The other authors do not have conflicts of interest to disclose. |
|
Date of release: February 2019 |
|
Expiration date: February 2022 |
Vol 80 - N° 2
P. 365-377 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?